Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin

BACKGROUND: Recently, it has been shown that 5-fluorouracil (5-FU) with a strong dihydropyrimidine dehydrogenase (DPD) inhibitor elicits a significant response in bladder cancer with a high level of DPD. However, only a few studies investigated the association between the level of the enzyme that re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ide, Hiroki, Kikuchi, Eiji, Mikami, Shuji, Miyajima, Akira, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169840/
https://www.ncbi.nlm.nih.gov/pubmed/25218240
http://dx.doi.org/10.1186/1756-0500-7-646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4169840/
https://www.ncbi.nlm.nih.gov/pubmed/25218240
http://dx.doi.org/10.1186/1756-0500-7-646

Ejemplares similares